The vision and Team behind ImmuneWatch
Our story
ImmuneWatch’s core mission is to crack one of the longest running challenges in systems immunology: predicting T-cell specificity with machine learning.
This journey started at the University of Antwerp and Antwerp University Hospital in Belgium when immunologists teamed up with biodata scientists within the AUDACIS consortium. The team pioneered the first work on using machine learning for TCR-epitope specificity predictions. Meanwhile, this collaboration led to more than 30 publications in the field of computational immunology.
Based on this success, ImmuneWatch was founded as a spin-off company and has since then significantly improved the technology, establishing themselves as world leaders in the field of TCR-epitope predictions.
The Team
The ImmuneWatch team unites a diverse range of experts, all driven by a shared mission: Annotating the epitope-specificity of TCRs.
Partnerships
ImmuneWatch is striving for excellence in its field and recognises the importance of strong strategic collaborations to achieve their goals.
Project partner in Yellow4FLAVI
Our scientific quest is to uncover the secrets of immunity conferred by the Yellow Fever virus YF17D vaccine. By deciphering these mechanisms, Yellow4FLAVI aims to lay the groundwork for the development of more effective and targeted flavivirus vaccines, addressing current and future health emergencies.
Launched at the start of 2024, ImmuneWatch will work together with:
Project partner in Yellow4FLAVI
Our scientific quest is to uncover the secrets of immunity conferred by the Yellow Fever virus YF17D vaccine. By deciphering these mechanisms, Yellow4FLAVI aims to lay the groundwork for the development of more effective and targeted flavivirus vaccines, addressing current and future health emergencies.
Launched at the start of 2024, ImmuneWatch will work together with:
Project partner in Yellow4FLAVI
Our scientific quest is to uncover the secrets of immunity conferred by the Yellow Fever virus YF17D vaccine. By deciphering these mechanisms, Yellow4FLAVI aims to lay the groundwork for the development of more effective and targeted flavivirus vaccines, addressing current and future health emergencies.
Launched at the start of 2024, ImmuneWatch will work together with:
Project partner in CAPTIVATE
CAPTIVATE, a new innovative European partnership to tackle hurdles in malaria vaccine development. With cutting-edge technologies and an unwavering commitment, the EU-funded CAPTIVATE project has the mission to create a next-generation malaria vaccine that targets multiple stages of the deadliest malaria parasite, P. falciparum.
Launched end of 2023, ImmuneWatch will work together with:
Project partner in CAPTIVATE
CAPTIVATE, a new innovative European partnership to tackle hurdles in malaria vaccine development. With cutting-edge technologies and an unwavering commitment, the EU-funded CAPTIVATE project has the mission to create a next-generation malaria vaccine that targets multiple stages of the deadliest malaria parasite, P. falciparum.
Launched end of 2023, ImmuneWatch will work together with:
Project partner in CAPTIVATE
CAPTIVATE, a new innovative European partnership to tackle hurdles in malaria vaccine development. With cutting-edge technologies and an unwavering commitment, the EU-funded CAPTIVATE project has the mission to create a next-generation malaria vaccine that targets multiple stages of the deadliest malaria parasite, P. falciparum.
Launched end of 2023, ImmuneWatch will work together with:
Quantoom Biosciences and the University of Antwerp.
Early 2023, ImmuneWatch entered into a public-private partnership with Quantoom Biosciences and the University of Antwerp. The goal of this project is to assess if a detailed analysis of the T-cell receptor response can be utilized to inform vaccine design and augment the vaccine development process. It is believed that the proposed methodology could reduce time and expenditures in the preclinical development process of vaccines. As a proof-of-concept, the team has chosen to work on a rabies vaccine candidate.
Quantoom Biosciences and the University of Antwerp.
Early 2023, ImmuneWatch entered into a public-private partnership with Quantoom Biosciences and the University of Antwerp. The goal of this project is to assess if a detailed analysis of the T-cell receptor response can be utilized to inform vaccine design and augment the vaccine development process. It is believed that the proposed methodology could reduce time and expenditures in the preclinical development process of vaccines. As a proof-of-concept, the team has chosen to work on a rabies vaccine candidate.
Quantoom Biosciences and the University of Antwerp.
Early 2023, ImmuneWatch entered into a public-private partnership with Quantoom Biosciences and the University of Antwerp. The goal of this project is to assess if a detailed analysis of the T-cell receptor response can be utilized to inform vaccine design and augment the vaccine development process. It is believed that the proposed methodology could reduce time and expenditures in the preclinical development process of vaccines. As a proof-of-concept, the team has chosen to work on a rabies vaccine candidate.
Find the epitope-specificity of your TCRs today
